Johnson & Johnson (JNJ) has now raised its dividend for 64 consecutive years, a run that spans multiple recessions, interest-rate cycles, patent cliffs, and restructurings. The streak cements the healthcare giant’s position as one of the most dependable income investments in a volatile market.
The board in April lifted the quarterly payout to $1.34 a share from $1.30, a 3.1% increase, and reaffirmed the dividend in July for the third quarter. Based on current prices, the annualized dividend is about $5.36 a share, yielding close to 2%. Including stock buybacks, total shareholder yield is higher. The payout ratio sits just below 47%, leaving room for reinvestment and risk absorption.
Johnson & Johnson operates through two divisions: Innovative Medicine and MedTech. The pharmaceutical unit sells branded therapies across oncology, immunology, neuroscience, and cardiopulmonary diseases. The device business produces surgical tools, cardiovascular equipment, orthopedic products, and contact lenses. The company has 28 platforms generating at least $1 billion in annual revenue, reducing reliance on any single product or market.
In the most recent quarter, total sales rose almost 7% to about $25.31 billion, driven by oncology and immunology drugs such as Darzalex and Tremfya. MedTech also grew, though it missed analyst estimates. Management raised full-year 2026 revenue guidance to about $101.1 billion and expects higher adjusted earnings per share than previously planned.
The MedTech segment is exiting the DePuy Synthes orthopedics business to focus on cardiovascular, surgery, and vision—areas with faster growth and higher margins. Acquisitions including Abiomed and Shockwave Medical have been integrated, and the company has filed for U.S. FDA approval of its Ottava robotic surgical system. On the pharmaceutical side, Johnson & Johnson plans to introduce at least 20 novel therapies or major product expansions by 2030.
Johnson & Johnson holds an AAA credit rating from S&P Global, higher than the U.S. government’s rating. The company said it has moved closer to resolving most talc-related lawsuits, easing a long-standing overhang. It also navigated the loss of U.S. exclusivity for Stelara, which accounted for nearly 12% of 2024 net sales, without derailing overall growth. Government-led drug price negotiations have created additional pressure, yet full-year guidance was still raised.
The 64-year record signals management treats the dividend as a commitment rather than a tool for good times alone. A diversified healthcare business, a conservative payout ratio, and measurable progress on legal risks reinforce Johnson & Johnson’s reputation as one of the safest dividend stocks available.
